Publicaciones en las que colabora con José Juan Rifón Roca (27)

2023

  1. Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia

    Frontiers in Immunology, Vol. 14

2022

  1. The bone marrow niche regulates redox and energy balance in MLL::AF9 leukemia stem cells

    Leukemia, Vol. 36, Núm. 8, pp. 1969-1979

2020

  1. A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia

    Blood Cancer Journal, Vol. 10, Núm. 1

  2. Strategy for identification of a potential inherited leukemia predisposition in a 299 patient's cohort with tumor-only sequencing data

    Leukemia Research, Vol. 95

2019

  1. Epigenomic profiling of myelofibrosis reveals widespread DNA methylation changes in enhancer elements and ZFP36L1 as a potential tumor suppressor gene that is epigenetically regulated

    Haematologica, Vol. 104, Núm. 8, pp. 1572-1579

2017

  1. First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study

    European Journal of Haematology, Vol. 98, Núm. 1, pp. 38-43

2013

  1. Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms

    Haematologica, Vol. 98, Núm. 9, pp. 1414-1420

2012

  1. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia

    Leukemia, Vol. 26, Núm. 7, pp. 1517-1526

  2. TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia

    PLoS ONE, Vol. 7, Núm. 2

2011

  1. Deregulation of FGFR1 and CDK6 oncogenic pathways in acute lymphoblastic leukaemia harbouring epigenetic modifications of the MIR9 family

    British Journal of Haematology, Vol. 155, Núm. 1, pp. 73-83

  2. Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in Acute Lymphoblastic Leukemia

    PLoS ONE, Vol. 6, Núm. 2

2010

  1. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia

    Blood, Vol. 115, Núm. 3, pp. 615-625

2009

  1. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia

    Cancer Research, Vol. 69, Núm. 10, pp. 4443-4453

2005

  1. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells

    Cancer Research, Vol. 65, Núm. 8, pp. 3264-3272

  2. Terapia celular

    Tratado de oncología pediátrica: Enfermedades malignas del niño y del adolescente (Pearson Educación), pp. 183-196

2004

  1. A single prior course of BCNU-cisplatin chemotherapy has a significant deleterious effect on mobilization kinetics of otherwise untreated patients

    Bone Marrow Transplantation, Vol. 33, Núm. 5, pp. 499-502

2001

  1. Thrombopenic purpura induced by a monoclonal antibody directed to a 35-kilodalton surface protein (p35) expressed on murine platelets and endothelial cells

    Experimental Hematology, Vol. 29, Núm. 5, pp. 589-595

1998

  1. Emergence of secondary acute leukemia in a patient treated for osteosarcoma: Implications of germline TP53 mutations

    Medical and Pediatric Oncology, Vol. 30, Núm. 3, pp. 165-169

1995

  1. Increased concentrations of tumor necrosis factor and lnterleukin-6 contribute to the hemostatic abnormalities in advanced liver disease

    Pathophysiology of Haemostasis and Thrombosis, Vol. 25, Núm. 6, pp. 305-311

1994

  1. Cytogenetic data in 41 patients with multiple myeloma. Karyotype and other clinical parameters

    Cancer Genetics and Cytogenetics, Vol. 78, Núm. 2, pp. 210-213